Latest Breast cancer chemotherapy Stories
BETHLEHEM, Pa., July 9, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today the company has achieved CE mark registration for its MyPaclitaxel(TM) and MyDocetaxel(TM) therapeutic dose management (TDM) MyCare(TM) assays, enabling commercialization in the European Union (EU). Saladax's MyCare technology...
A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators has identified a gene expression pattern that may explain why chemotherapy prior to surgery isn't effective against some tumors and suggests new therapy options for patients with specific subtypes of breast cancer. The study by lead author Justin Balko, Pharm.D., Ph.D., was published online June 10, 2012 in Nature Medicine in advance of print publication. Balko is a postdoctoral fellow in the laboratory of Carlos L....
Authors draw no specific recommendations due to size of study The most recent research released in June's Journal of Thoracic Oncology indicates there might be a positive correlation between tumor size and adjuvant platinum based chemotherapy in surgically resected patients with node negative non-small cell lung cancer. The study, published in the June 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, analyzed the effect of...
Results from a German study demonstrated no improvement in disease-free survival among patients with breast cancer who were treated with dose-dense chemotherapy and the bisphosphonate ibandronate. Volker Möbus, Ph.D., head of the department of obstetrics and gynecology at Klinikum Frankfurt Höchst GmbH in Frankfurt, presented the results from the German Adjuvant Intergroup Node Positive (GAIN) Study, at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011....
CAMBRIDGE, Mass., Oct. 11, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel (Taxol®) in the neoadjuvant setting of HER2-negative breast cancer patients. (Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO ) The Phase 2 study is designed to evaluate whether the combination of MM-121 with...
May reduce metastatic diseaseThe bone-strengthening drug zoledronic acid (Zometa) can help fight metastatic breast cancer when given before surgery, suggests research at Washington University School of Medicine in St. Louis.When the drug was given along with chemotherapy for three months before breast cancer surgery, it reduced the number of women who had tumor cells in their bone marrow at the time of surgery.The study was published in the May issue of The Lancet Oncology.Every day, tumors...
Women who discover they have breast cancer while they are pregnant can be treated with chemotherapy without endangering the health of their unborn baby, according to research to be presented at the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Friday).Dr Sibylle Loibl, Assistant Professor in Obstetrics and Gynecology at the University of Frankfurt, Germany, and a member of the German Breast Group, will tell the conference that pregnant breast cancer patients can be...
Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.Despite their resistance to drugs of the anthracycline class, the breast cancers bearing this gene signature will probably still be vulnerable to other types of chemotherapy agents, say scientists in a letter to be published in Nature Medicine on its Web site and later in a...
Finland, November 11 /PRNewswire/ -- - This is a third party press release. It will be issued by the Finnish Breast Cancer Group on Wednesday 11 November 2009. - FinXX, a Large, Phase III Randomised Study in Women With Early Breast Cancer Shows that Adding Capecitabine (Xeloda(R)) to a Treatment Regimen Containing Standard Agents Allows More Women to Live Cancer-Free for Longer An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology...
 In a study to determine the non-medical factors that may be associated with the decision to treat nonmetastatic breast cancer, researchers at Columbia University Mailman School of Public Health evaluated the association between oncologist characteristics and the receipt of chemotherapy in elderly women with breast cancer and found that they were more likely to receive chemotherapy if treated by oncologists employed in a private practice. For elderly women with localized breast cancer...
